| Trade Alert: Big News Pending for SIGA Technologies, Inc. | | Print | |
| Written by M.E.Garza | |||||||||||||||||||||||||
| Tuesday, 24 November 2009 00:00 | |||||||||||||||||||||||||
|
Subscribers were alerted yesterday that a series of big government orders are anticipated to be announced "any day now," after sources confirmed to us that the official news and first purchase order could come within days. The stock has a very, very low float and the price has been rising on just a little volume. It is not unrealistic to think that the stock could soar and see $15 -$20 range on the news (based on our own technical analysis). In May, SIGA announced that it had submitted its response to the Biomedical Advance Research and Development Authority (BARDA) regarding the agency's outstanding RFP for the procurement of 1.7 million courses of a smallpox antiviral. The U.S. government considers the inhaled smallpox virus the single biggest biological threat which could be used against Americans via a terrorist attack. SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). Please learn more about the company here: http://www.siga.com/ Disclosure: No Positions BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section Add this page to your favorite Social Bookmarking websites           
Set as favorite
Bookmark
Email this
Trackback(0)
Comments (11)
Kathleen Fuchs. M.D.
said:
|
TrackBack URI for this entry
Subscribe to this comment's feed|
... You mistakenly implied that the RFP (Request for Proposal) could come within days. The actual contract could be awarded any day now in response to the RFP. |
|
george wishington
said:
|
... this company holds 'no positions' because they are not interested in profiting from making forward looking statements nor are they interested in making money based on greed, fear, lust, pride, covetousness, envy or sloth, which, in all truth, makes them a great company to start a rumor |
|
meh
said:
|
... My guess is that he just keeps it there for tracking purposes. There is loads of stocks with only 1 share, all shorts in example. |
|
Mike Havrilla
said:
|
... kaChing is a virtual investing website and I do not have any short positions in any real money accounts. However, there is no reason to assume that I endorse, review, or approve stocks featured in articles that I do not write. Also, everyone should conduct their own due diligence and not blindly follow me or anyone else for their investments. |
|
Mike Havrilla
said:
|
... Meh, You are correct with regards to kaChing and the 1 share positions that I use for tracking purposes on the basis of % change. While I have never held a short position in any real money accounts, I think it is important to analyze all potential investments for the downside risk, relative valuation compared to peers, and short-term up / down momentum moves that may be unsustainable. |
|
Dereck
said:
|
... This is by far the best opportunity I have seen in the market in a long time. I never heard of any cure for any Virus, let alone the common cold. This compound should be a brakthrough in Medicine for years to come. Since it is a cure, the possibilities seem endless to me. I understand the potential of this Company, I'm locking my shares up in a Vault! |
|
Sign Up For Phone Alerts
